Related Experiment Video
Updated: Aug 4, 2026
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
Women's acceptability of and experience with primary human papillomavirus testing for cervix screening: HPV FOCAL
Laurie W Smith1,2, C Sarai Racey2,3, Lovedeep Gondara4
1Department of Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada laurie.smith@bccancer.bc.ca.
Objective:
To study participant's acceptability of and attitudes towards human papillomavirus (HPV) testing compared with cytology for cervical cancer screening and what impact having an HPV positive result may have in future acceptability of screening.
Design:
Cross-sectional online survey of clinical trial participants.
Setting:
Primary care, population-based Cervix Screening Program, British Columbia, Canada.
Participants:
A total of 5532 participants from the HPV FOCAL trial, in which women received HPV and cytology testing at study exit, were included in the analysis. Median age was 54 years. The median time of survey completion was 3 years after trial exit.
Outcome Measures:
Acceptability of HPV testing for primary cervical cancer screening (primary); attitudes and patient perceptions towards HPV testing and receipt of HPV positive screen results (secondary).
Results:
Most respondents (63%) were accepting of HPV testing, with the majority (69%) accepting screening to begin at age 30 years with HPV testing. Only half of participants (54%) were accepting of an extended screening interval of 4-5 years. In multivariable logistic regression, women who received an HPV positive screen test result during the trial (OR=1.41 95% CI 1.11 to 1.80) or were older (OR=1.01, 95% CI 1.00 to 1.02) were more likely to report HPV testing as acceptable.
Conclusions:
In this evaluation of acceptability and attitudes regarding HPV testing for cervix screening, most are accepting of HPV testing for screening; however, findings indicate heterogeneity in concerns and experiences surrounding HPV testing and receipt of HPV positive results. These findings provide insights for the development of education, information and communication strategies during implementation of HPV-based cervical cancer screening.
Trial Registration Numbers:
ISRCTN79347302 and NCT00461760.
